Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
10.12.2024 05:00:00 CET | Business Wire | Press release
Data presented at American Society of Hematology annual meeting
Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention and treatment of thromboembolic disorders, such as myocardial infarction, ischemic stroke, and venous thromboembolism. The trial data were presented during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA.
SRSD107 is designed to inhibit Factor XI (FXI), a protein in the coagulation pathway that has shown potential to reduce thrombosis without significantly increasing the risk of bleeding, a major liability of current drugs.
“In this trial, SRSD107 was safe and well tolerated, with pharmacokinetic parameters consistent with a typical siRNA product,” said Dr. Patrick Yue, Sirius’ Chief Medical Officer. “We are encouraged by the marked, prolonged reduction in FXI antigen and activity, and increase in clotting, or thromboplastin time, that are consistent potent anticoagulation over sustained periods and reduced bleeding risk respectively. The trial provides a strong foundation for Phase 2 clinical studies.”
Dr. Qunsheng Ji, Sirius’ Chief Executive Officer added that “presentation of these findings at ASH 2024 underscores Sirius Therapeutics' commitment to advancing innovative treatments for thromboembolic disorders.”
The study was a single-site, randomized double-blind, placebo controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneously administered SRSD107 in 40 healthy subjects. Five cohorts, each consisting of eight subjects evaluated eight doses of SRSD107, each receiving either a single SRSD107 dose or placebo. In the trial, SRSD107 was safe and well-tolerated. Significant changes from baseline in PD biomarkers were observed, with maximal reductions in FXI antigen and activity > 90% and an aPTT (thromboplastin time) increase of > 100% (i.e., an aPTT ratio > 2.0) at the highest doses tested. The pharmacodynamic effects were durable, with FXI antigen and activity levels remaining suppressed for more than 16 weeks after dosing.
The study is titled, “A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects. For more information on the study and our ongoing clinical trials, please visit Sirius Therapeutics' website (www.siriusrna.com) or here.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality rates, thromboembolic disorders are estimated to cause as many as 1 in 4 deaths worldwide.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets human coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to translating siRNA technology into transformative medicine for patients with chronic diseases. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209815845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Simon-Kucher Selects Navan to Modernize Global Travel Program24.2.2026 11:00:00 CET | Press release
Global consultancy to consolidate travel operations with Navan across more than a dozen markets Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Simon-Kucher, the world’s leading commercial growth and pricing consultancy, as its global travel partner. Simon-Kucher teams will now have access to Navan’s AI-powered travel management platform across more than a dozen markets, including in the North American, European, and APAC regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224745907/en/ Simon-Kucher Selects Navan to Modernize Global Travel Program “Our work is increasingly global, and travel remains essential to how we collaborate with clients and with one another,” said Thomas Wohlan, Director of Travel Management at Simon-Kucher. “To support that at scale, we needed a modern travel platform that brings consistency across countries and simplifi
Khazna Awarded Uptime Tier III Certification of Design Documents for Ajman, UAE Facility, Largest in Company’s Portfolio24.2.2026 10:00:00 CET | Press release
Set to Achieve 1st Certified AI Data Center with Liquid Cooling in Middle East Uptime Institute, the Global Digital Infrastructure Authority, today announced that Khazna Data Centers, a global leader in hyperscale digital infrastructure, has achieved the Uptime Institute Tier III Certification of Design Documents (TCDD) award for its newest 100 MW AI-optimized data center, QAJ01 —set to be the first certified AI data center with liquid cooling in the Middle East and North Africa region. Representing the largest facility in Khazna’s portfolio, this state-of-the-art development features 20 data halls, each delivering 5 MW of IT capacity, purpose-built to meet the demands of next-generation artificial intelligence (AI) workloads. The certification underscores Khazna’s commitment to designing world-class, resilient, and efficient data center infrastructure in alignment with the industry’s most rigorous global standards. Located in Ajman, United Arab Emirates, the new facility has been desi
Infobip and ESA Boost Asteroid Impact Alerts with Instant Voice Calls24.2.2026 10:00:00 CET | Press release
New partnership accelerates response times for critical planetary defense alerts Global cloud communications platform, Infobip, has partnered with the European Space Agency (ESA) to improve the delivery of asteroid impact alerts via Infobip's Voice API solutions. Using Infobip’s platform, ESA personnelnow receive instant voice calls, enabling faster, 24/7 alerts for potential asteroid impacts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224294384/en/ European Space Agency partners with Infobip for asteroid impact alerts. Understanding the trajectories of asteroids, particularly those approaching Earth, known as near-Earth objects (NEOs), is crucial and time sensitive. As single asteroid impact 65 million years ago wiped out most life on Earth, it is vital for the ESA to identify all hazardous asteroids to better understand their physical characteristics and the potential consequences of an impact. Previously, ESA perso
ElevenEs held 1st Closing of its Series B Investment Round Backed by Caterpillar Venture Capital Inc.24.2.2026 09:24:00 CET | Press release
Construction of its 1GWh LFP Battery Cell Mega Factory to Begin in February 2026. ElevenEs has completed the first closing of its Series B investment round, backed by Caterpillar Venture Capital Inc., a wholly owned subsidiary of Caterpillar Inc. (NYSE: CAT) - the world’s leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Additionally, an affiliate of BST (HK) Ltd., a leading Hong Kong-based commodity trading house, participated in the round. This transaction represents a significant milestone in the future of European battery manufacturing as the proceeds will be used for the initial phases of infrastructure and equipment toward the planned 1GWh Mega-Factory, with construction starting in February 2026. The first battery cell deliveries are expected in 2027. This project positions ElevenEs at the forefront of the global energy transition and marks a significant step forward in
PUR Appoints Dr. Daniel Klier as Chief Executive Officer24.2.2026 09:00:00 CET | Press release
Seasoned sustainability and climate finance leader to guide PUR’s next phase of growth PUR (the “Company”), a pioneer in Nature-based Solutions, today announced the appointment of Dr. Daniel Klier as Chief Executive Officer, subject to regulatory approval. Founded nearly two decades ago, PUR partners with farming communities globally to deliver agroforestry, reforestation, and landscape restoration projects. The Company generates verified carbon reductions and carbon credits that help corporates reduce supply chain emissions through high-integrity insetting and climate contributions within and beyond their own value chains, while improving soil health, water resources, and long-term farm productivity. PUR is a recognized leader in resilient coffee and cocoa value chains, reforestation, mangrove restoration, and ecosystem conservation, delivering measurable benefits for ecosystems, agriculture, and farming communities. Dr. Klier’s appointment marks the next phase of PUR’s development as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom